Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$5.64 USD
-0.04 (-0.70%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $5.65 +0.01 (0.18%) 6:08 PM ET
4-Sell of 5 4
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Capricor Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 25 | 3 | 0 | 0 | 1 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 25 | 3 | 0 | 0 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 49 | 32 | 21 | 14 | 9 |
Income After Depreciation & Amortization | -24 | -30 | -21 | -14 | -8 |
Non-Operating Income | 2 | 1 | 1 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -22 | -29 | -20 | -14 | -8 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -22 | -29 | -20 | -14 | -8 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -22 | -29 | -20 | -14 | -8 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -23 | -29 | -21 | -14 | -8 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -24 | -30 | -21 | -14 | -8 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 26.78 | 24.55 | 23.09 | 15.57 | 3.71 |
Diluted EPS Before Non-Recurring Items | -0.83 | -1.18 | -0.87 | -0.88 | -2.06 |
Diluted Net EPS (GAAP) | -0.83 | -1.18 | -0.87 | -0.88 | -2.06 |
Fiscal Year end for Capricor Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 4.91 | 12.09 | 6.19 | 3.92 | 2.99 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 4.91 | 12.09 | 6.19 | 3.92 | 2.99 |
SG&A, R&D, and Dept/Amort Expenses | 15.17 | 13.37 | 13.05 | 11.67 | 11.17 |
Income After SG&A, R&D, and Dept/Amort Expenses | -10.26 | -1.28 | -6.86 | -7.75 | -8.18 |
Non-Operating Income | 0.47 | 0.45 | 0.47 | 0.38 | 0.42 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -9.79 | -0.76 | -6.39 | -7.37 | -7.77 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -9.79 | -0.76 | -6.39 | -7.37 | -7.77 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -9.79 | -0.76 | -6.39 | -7.37 | -7.77 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 31.36 | 30.66 | 25.82 | 25.34 | 25.25 |
Diluted EPS Before Non-Recurring Items | -0.31 | -0.02 | -0.25 | -0.29 | -0.31 |
Diluted Net EPS (GAAP) | -0.31 | 0.02 | -0.25 | -0.29 | -0.31 |